A clinical formulation indicated for Antivirals. This treatment assists with the management of chronic viral activity to promote long-term cellular health.
An antiviral agent utilized to manage chronic Hepatitis C infection and intended to support viral clearance to alleviate liver inflammation and target long-term recovery.
Mechanism of Action
It inhibits the HCV NS5A protein, which is vital for viral replication and assembly. This stops the virus from spreading and multiplying in the liver.
Route of Administration
Oral
Onset Time
Variable
Duration
24 hours
Contraindications
Concurrent use of strong CYP3A inducers, Allergy to daclatasvir
Severe Adverse Events
Hepatitis B reactivation, Severe bradycardia (with amiodarone), Liver failure, Severe allergic reaction
Common Side Effects
Headache, Fatigue
Uncommon Side Effects
Nausea, Diarrhea, Skin rash, Anemia
Drug Interactions
Amiodarone, Rifampin, Carbamazepine, St. John's wort, Statins
Information for Daklinza is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
